Medipixel announced that it has raised $1M from QUAD investment management. Medipixel plans to boost its product portfolio development from cardiovascular disease diagnosis to automated navigation of intervention tools.

Andy Song, CEO of Medipixel, said, “2020 will be the first year that Medipixel is releasing its own product, and it will make coronary intervention more effective, productive, and economically feasible.”

It is said that Medipixel has published/prepared various patents and academic papers for gathering clinical evidences for its products.